AGEN
Agenus IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$149.37M
P/E Ratio
0.00
EPS
$0.00
Beta
1.61
52W High
$7.34
52W Low
$2.70
50-Day MA
$3.62
200-Day MA
$4.06
Dividend Yield
—
Profit Margin
0.10%
Forward P/E
1.86
PEG Ratio
1.44
About Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Fundamentals
| Revenue (TTM) | $114.20M |
| Gross Profit (TTM) | $110.22M |
| EBITDA | $-10.56M |
| Operating Margin | 42.10% |
| Return on Equity | -1279.00% |
| Return on Assets | -5.67% |
| Revenue/Share (TTM) | $3.84 |
| Book Value | $-7.68 |
| Price-to-Book | 218.61 |
| Price-to-Sales (TTM) | 1.31 |
| EV/Revenue | 1.839 |
| EV/EBITDA | 3.38 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 27.50% |
| Shares Outstanding | $38.40M |
| Float | $35.62M |
| % Insiders | 7.23% |
| % Institutions | 27.24% |
Historical Volatility
HV 10-Day
87.56%
HV 20-Day
109.68%
HV 30-Day
94.01%
HV 60-Day
90.90%
HV Rank
50.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.50 target)
2
Buy1
HoldData last updated: 4/29/2026